MA55199B1 - (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques - Google Patents

(n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques

Info

Publication number
MA55199B1
MA55199B1 MA55199A MA55199A MA55199B1 MA 55199 B1 MA55199 B1 MA 55199B1 MA 55199 A MA55199 A MA 55199A MA 55199 A MA55199 A MA 55199A MA 55199 B1 MA55199 B1 MA 55199B1
Authority
MA
Morocco
Prior art keywords
leucine
pharmaceutically acceptable
acceptable salt
acetyl
brain injury
Prior art date
Application number
MA55199A
Other languages
English (en)
Other versions
MA55199A (fr
Inventor
Mallory Factor
Taylor FIELDS
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MA55199A publication Critical patent/MA55199A/fr
Publication of MA55199B1 publication Critical patent/MA55199B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés de traitement de maladies, de troubles, d'états ou de syndromes, par exemple d'une lésion cérébrale traumatique, chez un patient en ayant besoin par l'administration d'une quantité thérapeutiquement efficace de DL-leucine, ou d'un sel pharmaceutiquement acceptable de celle-ci, de L-leucine, ou d'un sel pharmaceutiquement acceptable de celle-ci, de D-leucine, ou d'un sel pharmaceutiquement acceptable de celle-ci, d'un ester d'éthyle de L-leucine, ou d'un sel pharmaceutiquement acceptable de celui-ci, d'acétyl-DL-leucine, ou d'un sel pharmaceutiquement acceptable de celle-ci, d'acétyl-D-leucine, ou d'un sel pharmaceutiquement acceptable de celle-ci, ou d'acétyl-L-leucine, ou d'un sel pharmaceutiquement acceptable de celle-ci.
MA55199A 2019-03-02 2020-03-02 (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques MA55199B1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962812987P 2019-03-02 2019-03-02
US201962842296P 2019-05-02 2019-05-02
US201962888894P 2019-08-19 2019-08-19
US201962895144P 2019-09-03 2019-09-03
EP20712029.6A EP3934637B1 (fr) 2019-03-02 2020-03-02 (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques
PCT/IB2020/051767 WO2020178721A1 (fr) 2019-03-02 2020-03-02 Leucine, acétyl leucine et analogues apparentés pour le traitement d'une maladie

Publications (2)

Publication Number Publication Date
MA55199A MA55199A (fr) 2022-01-12
MA55199B1 true MA55199B1 (fr) 2024-08-30

Family

ID=69845470

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55199A MA55199B1 (fr) 2019-03-02 2020-03-02 (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques

Country Status (25)

Country Link
US (1) US20220142959A1 (fr)
EP (2) EP4464378A3 (fr)
JP (2) JP7555346B2 (fr)
KR (2) KR20250171484A (fr)
CN (2) CN119097618A (fr)
AU (2) AU2020231189B2 (fr)
BR (1) BR112021017203A2 (fr)
CA (1) CA3131948A1 (fr)
DK (1) DK3934637T3 (fr)
ES (1) ES2990183T3 (fr)
FI (1) FI3934637T3 (fr)
HR (1) HRP20241150T1 (fr)
HU (1) HUE068527T2 (fr)
IL (2) IL321899A (fr)
LT (1) LT3934637T (fr)
MA (1) MA55199B1 (fr)
MD (1) MD3934637T2 (fr)
MX (2) MX2021010568A (fr)
PL (1) PL3934637T3 (fr)
PT (1) PT3934637T (fr)
RS (1) RS65849B1 (fr)
SG (1) SG11202109512SA (fr)
SI (1) SI3934637T1 (fr)
SM (1) SMT202400334T1 (fr)
WO (1) WO2020178721A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
BR112021010923A2 (pt) * 2018-12-06 2021-08-24 Intrabio Ltd Análogos deuterados de acetileucina
WO2022125304A1 (fr) * 2020-12-10 2022-06-16 Texas Tech University System Composés de réduction de bcaa pour la prévention et/ou le traitement de la maladie d'alzheimer et de troubles apparentés
WO2022264037A1 (fr) * 2021-06-14 2022-12-22 Intrabio Ltd. Dérivés d'acides aminés à chaîne ramifiée pour traiter une maladie
WO2024243004A2 (fr) * 2023-05-19 2024-11-28 The Children's Hospital Of Philadelphia Compositions et procédés de traitement d'une lésion cérébrale traumatique
WO2025166100A1 (fr) * 2024-02-02 2025-08-07 SynGAP Research Fund Compositions et méthodes de traitement de troubles neurodéveloppementaux
WO2025175092A1 (fr) * 2024-02-14 2025-08-21 Intrabio Inc. Acétylleucine pour le traitement de troubles liés à syngap1
TW202604470A (zh) * 2024-06-20 2026-02-01 美商音特拉拜歐公司 乙醯白胺酸用於治療神經發育障礙

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
EP2588130B1 (fr) 2010-06-25 2016-08-17 Shire Human Genetic Therapies, Inc. Administration au snc d'agents thérapeutiques
US20140080885A1 (en) * 2012-09-13 2014-03-20 University Of South Florida (A Florida Non-Profit Corporation) Methods of treating traumatic brain injury
WO2017182802A1 (fr) * 2016-04-19 2017-10-26 Intrabio Ltd Acétyl-leucine ou sel pharmaceutiquement acceptable de celle-ci pour une mobilité améliorée et une fonction cognitive
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
MA43828B1 (fr) 2016-08-11 2019-09-30 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
KR102467953B1 (ko) 2016-08-11 2022-11-16 인트라바이오 리미티드 리소좀 축적 질환과 관련된 약제 조성물 및 용도
JP7370960B2 (ja) * 2017-08-14 2023-10-30 アクセラ・ヘルス・インコーポレイテッド 神経細胞損傷の治療のためのアミノ酸組成物

Also Published As

Publication number Publication date
JP7555346B2 (ja) 2024-09-24
BR112021017203A2 (pt) 2021-12-14
PT3934637T (pt) 2024-08-30
IL285870B2 (en) 2025-12-01
KR102941068B1 (ko) 2026-03-18
ES2990183T3 (es) 2024-11-29
JP2022522819A (ja) 2022-04-20
AU2020231189A1 (en) 2021-09-30
IL285870A (en) 2021-10-31
EP3934637A1 (fr) 2022-01-12
CN114040757B (zh) 2024-09-20
KR20250171484A (ko) 2025-12-08
US20220142959A1 (en) 2022-05-12
RS65849B1 (sr) 2024-09-30
EP3934637B1 (fr) 2024-07-31
WO2020178721A1 (fr) 2020-09-10
AU2025204995A1 (en) 2025-07-17
PL3934637T3 (pl) 2024-10-14
MD3934637T2 (ro) 2024-12-31
CN119097618A (zh) 2024-12-10
EP4464378A2 (fr) 2024-11-20
AU2020231189B2 (en) 2025-07-24
MX2024015063A (es) 2025-01-09
CN114040757A (zh) 2022-02-11
SG11202109512SA (en) 2021-09-29
KR20210135272A (ko) 2021-11-12
CA3131948A1 (fr) 2020-09-10
JP2024170602A (ja) 2024-12-10
IL285870B1 (en) 2025-08-01
HRP20241150T1 (hr) 2024-11-22
FI3934637T3 (fi) 2024-09-02
EP4464378A3 (fr) 2025-04-09
MA55199A (fr) 2022-01-12
HUE068527T2 (hu) 2025-01-28
SI3934637T1 (sl) 2024-10-30
IL321899A (en) 2025-09-01
DK3934637T3 (da) 2024-09-02
MX2021010568A (es) 2021-11-12
LT3934637T (lt) 2024-08-26
SMT202400334T1 (it) 2024-09-16

Similar Documents

Publication Publication Date Title
MX2024015063A (es) Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MXPA04004552A (es) Compuestos tipo indolizina sustituida y metodos de uso.
RU2015107877A (ru) Способы лечения болезни альцгеймера и фармацевтические композиции
DE60331537D1 (de) Kombinationen zur behandlung von multiplem myelom
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
EA202190586A1 (ru) N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
ZA202205149B (en) Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
WO2023081482A9 (fr) Association de sodium phénylbutyrate et de taurursodiol pour le traitement de maladies neurodégénératives
MX2023002350A (es) Composiciones y metodos para mejorar enfermedades y trastornos neurologicos.
EP4585269A3 (fr) Procédés de thérapie anticancéreuse
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MX2022006083A (es) Metodos para tratar afecciones relacionadas con el receptor s1p1.
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
TN2010000108A1 (fr) Traitement de symtomes vasomoteurs
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
MX2019003720A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
JP2021521227A5 (fr)
WO2022048618A8 (fr) Méthodes de traitement des maladies inflammatoires de l'intestin
ATE248607T1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
EA200702534A1 (ru) Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2)